Edition:
United States

AMAG Pharmaceuticals Inc (AMAG.O)

AMAG.O on Nasdaq

18.20USD
22 Sep 2017
Change (% chg)

$-0.25 (-1.36%)
Prev Close
$18.45
Open
$18.35
Day's High
$18.50
Day's Low
$18.05
Volume
540,347
Avg. Vol
947,379
52-wk High
$36.83
52-wk Low
$16.00

Summary

Name Age Since Current Position

Gino Santini

60 2014 Independent Chairman of the Board

William Heiden

57 2017 President, Chief Executive Officer, Director

Edward Myles

45 2016 Chief Financial Officer, Senior Vice President - Finance, Treasurer

Nathan McBride

Senior Vice President - Innovation Architects, Chief Information Officer

Joseph Vittiglio

45 2016 Senior Vice President - Legal Affairs, Technical Operations and Quality, General Counsel, Secretary

Tony Casciano

2016 Senior Vice President of Sales and Marketing - Hematology and Oncology business

Paul Williams

Senior Vice President - Sales and Marketing, Women’s Health

Elizabeth Bolgiano

Senior Vice President of Human Resources

Julie Krop

51 2015 Chief Medical Officer and Senior Vice President - Clinical Development and Regulatory Affairs

Scott McMillan

2013 Senior Vice President - Quality and Technical Operations

Laura Williams

2017 Senior Vice President - Clinical Development

Helen Milton

2017 Vice President - Regulatory Affairs

Kathryn Payne

2015 Vice President - External Affairs.

Oscar Sanchez

2017 Vice President - Quality

Arpad Simon

2017 Vice President - Pharmacovigilance

Mark Stanton

2016 Vice President - Market Access and Corporate Accounts

Nicholas Grund

47 2016 Chief Commercial Officer

Barbara Deptula

62 2013 Independent Director

John Fallon

69 2014 Independent Director

Robert Perez

52 2009 Independent Director

Cooper Russell

56 2009 Independent Director

Davey Scoon

71 2006 Independent Director

James Sulat

66 2014 Independent Director

Linda Lennox

2015 Vice President - Investor Relations and Corporate Communications

Biographies

Name Description

Gino Santini

Mr. Gino Santini is Independent Chairman of the Board of the Company. From 1983 to 2010, Mr. Santini held a variety of commercial and operational roles at Eli Lilly and Company ("Eli Lilly"), a public pharmaceutical company, serving most recently from 2007 to 2010, as Senior Vice President, Corporate Strategy and Business Development, where he led corporate strategy and long-range planning, mergers and acquisitions, new product licensing and the expansion of Lilly Ventures in the U.S. and China. During his tenure at Eli Lilly, Mr. Santini held various leadership positions of increasing responsibility, including manager of various international regions, Senior Vice President of Corporate Strategy and Policy from 2004 to 2007, President of U.S. operations from 1999 to 2004 and President of the women's health franchise from 1997 to 1999. Mr. Santini has served on the Board of Directors of Intarcia Therapeutics, Inc., a biopharmaceutical company, since July 2013 and on the Board of Directors of Collegium Pharmaceuticals, Inc., a public pharmaceutical company, since July 2012, where he is also the chair of the Nominating & Corporate Governance Committee and a member of the Compensation Committee. Mr. Santini has also served on the Board of Directors of Allena Pharmaceuticals, Inc., a specialty pharmaceutical company, since 2012, Artax Biopharma Inc., a biopharmaceutical company, since April 2014 and Intercept Pharmaceuticals, Inc. a public biopharmaceutical company, since December 2015, where he is also the chair of the Compensation Committee and a member of the Audit Committee. He holds an undergraduate degree in mechanical engineering from the University of Bologna and an M.B.A. from the Simon School of Business, University of Rochester.

William Heiden

Mr. William K. Heiden is President, Chief Executive Officer, Director of the Company effective April 30, 2017. Prior to joining AMAG, he was the President and Chief Executive Officer of GTC Biotherapeutics, Inc., now rEVO Biologics, Inc., a pharmaceutical company ("GTC"), from 2010 to May 2012. Mr. Heiden was President and Chief Executive Officer and a member of the Board of Directors of Elixir Pharmaceuticals, Inc. ("Elixir") from 2004 to 2008. Prior to joining Elixir, he served as President and Chief Operating Officer of Praecis Pharmaceuticals, Inc., which was subsequently acquired by GlaxoSmithKline plc, from 2002 to 2004. From 1987 to 2002, Mr. Heiden held various positions of increasing responsibility at Schering-Plough Corporation, now Merck & Co., including managing a number of businesses in the United States, Europe and Canada. From 2006 to October 2013, he served on the Board of Directors of LFB Biotechnologies S.A.S., a private French biotechnology company, and from 2007 to October 2013, Mr. Heiden served as Chairman of the Board of Directors of GTC. He currently serves on the Board of Directors of Atara Biotherapeutics, Inc. a public biopharmaceutical company, and the Board of Directors of Pharmaceutical Research and Manufacturers of America (PhRMA). Mr. Heiden holds a B.A. from the University of Florida, an M.B.A. from Cornell University's Johnson Graduate School of Management, and a M.I.M. from the University of Louvain.

Edward Myles

Mr. Edward Myles, CPA is Chief Financial Officer, Senior Vice President - Finance, Treasurer of the Company. Prior to joining the Company, Mr. Myles served in various positions at Ocata Therapeutics, Inc. (“Ocata”), from June 2013 to April 2016, most recently as Chief Financial Officer and Chief Operating Officer. Prior to Ocata, Mr. Myles served as Chief Financial Officer and Vice President of Operations at PrimeraDx, Inc. from November 2008 to June 2013. He also served as Senior Vice President of Finance and Chief Financial Officer at Pressure Biosciences, Inc. from April 2006 to November 2008 and Controller at EMD Pharmaceuticals, Inc. (a wholly-owned subsidiary of Merck KGaA) from May 2003 to April 2006. Earlier in his career, Mr. Myles was an Associate in the healthcare investment banking group at SG Cowen Securities Corporation and served as Corporate Controller for Boston Biomedica, Inc. Mr. Myles began his career at PriceWaterhouseCoopers LLP where he served a variety of clients in the life sciences and technology industries. Mr. Myles holds a bachelor’s of science degree in business administration from University of Hartford and an M.B.A. from the John M. Olin School of Business, Washington University.

Nathan McBride

Mr. Nathan McBride is Senior Vice President - Innovation Architects, Chief Information Officer of the company. He has more than 18 years of experience managing both small and large information technology teams primarily in the biopharmaceutical industry. He joined AMAG in January 2008 and is responsible for all information technology operations including business management software integrations for key corporate initiatives, security, application development, database design and enterprise wide implementations. He is also responsible for the facilities management of all properties leased by AMAG. Prior to joining AMAG, he served as senior director of business and scientific applications at Cubist Pharmaceuticals from 2005 to 2008. Prior to his time at Cubist, Mr. McBride served as senior director of information technology at Transkaryotic Therapies, Inc., now Shire Pharmaceuticals, from 1999 to 2005 and the director of technology at Cushing Academy from 1997 to 1999. He began his career in information technology in 1996 as an assistant manager and teacher at Rye Country Day School. Mr. McBride holds a bachelor of arts in classics degree from Connecticut College.

Joseph Vittiglio

Mr. Joseph D. Vittiglio is Senior Vice President - Legal Affairs, Technical Operations and Quality, General Counsel, Secretary of the Company. He served from March 2015 to August 2015 as Vice President of Legal Affairs and a member of the Management Committee at Flexion Therapeutics, Inc. ("Flexion"), a public pharmaceutical company. Prior to Flexion, Mr. Vittiglio was the General Counsel and Secretary of AVEO Pharmaceuticals, Inc., a public biopharmaceutical company, from 2007 to March 2015. From 2005 to 2007, he served as Director of Corporate Legal Affairs at Oscient Pharmaceuticals Corporation ("Oscient"), a public pharmaceutical company. Prior to Oscient, Mr. Vittiglio was a senior corporate associate from 1998 to 2005 at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo PC. Mr. Vittiglio holds a B.A. in International Relations from Tufts University and a J.D. from Northeastern University School of Law.

Tony Casciano

Mr. Tony Casciano is Senior Vice President - Sales and Marketing - Hematology and Oncology business of the Company. Mr. Casciano brings to AMAG more than 15 years of sales and marketing experience and began his career at Sanofi US in 2000. He has advanced through commercial positions of increasing responsibility across a broad range of therapeutic areas, and most recently served as the head of marketing for Sanofi where he led the General Medicine division. Mr. Casciano holds a Bachelor of Science degree in business administration from Bridgewater State College.

Paul Williams

Mr. Paul Williams is Senior Vice President - Sales and Marketing, Women’s Health of the company. He serves as senior vice president of sales and marketing for the Lumara Health and Cord Blood Registry (CBR) divisions of AMAG. Mr. Williams joined AMAG with more than 25 years of sales and marketing experience as part of the company’s acquisition of Lumara Health in November 2014. As vice president of the women’s healthcare division and commercial operations of Lumara Health, he led the build-out and re-launch of the company’s product portfolio in anti-infectives and hormone replacement therapy. Prior to joining Lumara Health, Mr. Williams served as senior vice president and general manager of a division of Actavis, Inc. Prior to Actavis, Mr. Williams held positions of increasing sales and marketing responsibility at Medimmune LLC, a member of the AstraZeneca Group, and Centocor, Inc., a Johnson & Johnson Company. Mr. Williams holds a bachelor’s of science degree in finance from Virginia Polytechnic Institute and State University.

Elizabeth Bolgiano

Ms. Elizabeth Bolgiano is Senior Vice President - Human Resources of the company. She is an experienced human resources professional who joined AMAG in January 2014 as senior vice president of human resources. Ms. Bolgiano joined AMAG Pharmaceuticals from Thermo Fisher Scientific where she served as senior vice president of human resources and a member of the executive team since 2010. Prior to joining Thermo Fisher Scientific, Ms. Bolgiano served as group human resources director of Smith & Nephew Company from 2007 to 2010 and senior vice president of human resources from 2004 to 2006. From 1989 to 2004, Ms. Bolgiano progressed through various positions of increasing responsibility at Bristol-Myers Squibb Company. Ms. Bolgiano has significant experience across the spectrum of human resources including organizational development, strategy, talent acquisition, employee relations, compensation, and leadership development and training. She holds a Master’s degree in business administration, as well as a Bachelor’s degree, from Cornell University.

Julie Krop

Ms. Julie Krop, M.D. is Chief Medical Officer and Senior Vice President - Clinical Development and Regulatory Affairs of the Company. Prior to joining us, Dr. Krop served from 2012 to May 2015 in roles of increasing responsibility at Vertex Pharmaceuticals, Inc. ("Vertex"), a public biotechnology company, where she most recently served as Vice President, Clinical Development. Prior to Vertex, Dr. Krop held various positions at Stryker Corporation, a public medical technology company, from 2006 to 2011, where she most recently served as Vice President, Clinical Development and Regulatory Affairs. Prior to her work at Stryker Corporation, Dr. Krop served as Vice President, Clinical Research at Peptimmune Inc., a biotechnology company, from 2003 to 2006, Director of Clinical Research at Millennium Pharmaceuticals, Inc., a public biopharmaceutical company (which was subsequently acquired by Takeda Pharmaceutical Company Limited), from 2001 to 2003 and Associate Director at Pfizer Inc., a public biopharmaceutical company, from 1999 to 2001. Dr. Krop holds a B.S. from Brown University and her medical degree from the Warren Alpert Medical School of Brown University. She completed her residency in the Department of Medicine at Georgetown University Hospital and a fellowship in the Department of Endocrinology at the Johns Hopkins University School of Medicine. In addition, Dr. Krop was a Robert Wood Johnson Foundation Clinical Scholar.

Scott McMillan

Dr. Scott T. McMillan, Ph.D. is Senior Vice President - Quality and Technical Operations of the company. Since January 2013, he was promoted to senior vice president, quality and technical operations. Dr. McMillan joined AMAG from AVANT Immunotherapeutics, Inc. (now Celldex Therapeutics, Inc.), a public biopharmaceutical company, where he held various roles of increasing responsibility from 2005 to 2008, including senior director, manufacturing operations/process development. Prior to his time with AVANT, he was director, purification operations at Johnson Matthey Pharmaceutical Materials, Inc., an international specialty chemicals company. Dr. McMillan holds a B.S. in Chemical Engineering from the University of Delaware and a Ph.D. in Chemical Engineering from the Georgia Institute of Technology. Since 2010, he has served as a member of the Industrial Advisory Board of the Department of Chemical Engineering at Northeastern University.

Laura Williams

Dr. Laura Williams, M.D., M.P.H., serves as Senior Vice President - Clinical Development of the Company. Dr. Williams has more than 20 years of pharmaceutical experience, spanning all phases of drug development and across numerous therapeutic areas, including her more recent work with compounds and products aimed at solving unmet medical needs in women's health. In her role at AMAG, Dr. Williams is responsible for the overall strategy and execution of clinical development activities, including study design and data interpretation. She will work with the regulatory, quality, clinical and technical operations teams to support new drug development, as well as regulatory filings and approvals. Prior to joining AMAG, she served as vice president of clinical development at Myovant Sciences, where she oversaw clinical development for an infertility treatment and co-led business development activities to expand the women's health pipeline. Previously, she held roles of increasing responsibility at Abbott and AbbVie where her most recent key achievements included leading the development program for an oral GnRH antagonist in women's health and advancing that mid-late stage asset through multiple key drug development milestones. At Abbott, she also served as global project head of numerous clinical development teams across a range of therapeutic areas. Dr. Williams received a medical degree from University of Iowa College of Medicine, a Master of Public Health in Epidemiology from University of Washington School of Public Health and a Bachelor of Science from Mississippi State University. She completed her residency at University of Michigan Hospitals and Clinics and a fellowship in Infectious Diseases at University of Washington Hospitals and Clinics.

Helen Milton

Ms. Helen Milton, Ph.D. was Vice President - Regulatory Affairs of the company. Dr. Milton will have responsibility for AMAG's regulatory activities, including leading the strategic direction and regulatory approach for all products. She will also oversee the company's upcoming regulatory filings, which include a supplemental new drug application submission in mid-2017 to potentially broaden the Feraheme® (ferumoxytol) label beyond its current indication, as well as the submission of a new drug application in early 2018 for bremelanotide, an investigational product for the treatment of hypoactive sexual desire disorder.

Kathryn Payne

Ms. Kathryn Carr Payne is Vice President - External Affairs of the company. She is directs AMAG’s communications and public affairs activities, which include leading the company’s public relations and policy and advocacy initiatives at the state and federal level. Ms. Payne has nearly 15 years of experience in public relations and issue advocacy, specializing in using communications and stakeholder engagement to advance business and policy objectives. She joined AMAG in May 2014 from APCO Worldwide, a global public affairs and strategic communications firm based in Washington D.C., where she spent 10 years in various positions of increasing responsibility, including most recently as vice president and director. During her time at APCO, Ms. Payne led corporate communications, policymaker outreach and brand-building programs designed to position pharmaceutical and biotechnology companies, their products, issues and leadership to external audiences, including media, investors, customers and patients. Prior to joining APCO, Ms. Payne served as a communications associate at the World Bank in Washington, D.C., and as a healthcare research associate at Forrester Research, a publicly traded research and advisory firm based in Cambridge, Mass. Ms. Payne graduated Phi Beta Kappa and with high honors from The Johns Hopkins University with a bachelor’s degree in writing and business management and a master’s degree in communications.

Oscar Sanchez

Mr. Oscar Sanchez serves as Vice President - Quality of the Company. In his role at AMAG, Mr. Sanchez is responsible for creating and implementing programs, policies and procedures related to quality assurance and quality control activities across the company's commercially-available therapeutics, multiple development stage products and cord blood banking services. He will also provide compliance oversight of activities involving recognized quality standards, such as good manufacturing practices and good clinical practices, as well as accreditations and industry certifications. Mr. Sanchez has more than 25 years of experience in the pharmaceutical and medical device industries, serving in leadership roles at organizations such as Albany Molecular Research Institute, MAQUET, Novartis and General Electric Healthcare, among others. Mr. Sanchez holds a bachelor's of science degree from Excelsior College in Albany, NY. He is also a certified Six Sigma Master Black Belt.

Arpad Simon

Dr. Arpad Simon, M.D. is Vice President - Pharmacovigilance of the Company. Dr. Simon will have responsibility for all pharmacovigilance functions at AMAG, including product safety surveillance, aggregate safety reporting and risk management. He will also oversee safety evaluation across the company's clinical development activities and marketed therapeutics. In addition to his leading roles in the pharmaceutical industry both from a U.S. and global perspective, Dr. Simon also worked for five years at the FDA Center for Drug Evaluation and Research. He has successfully led and managed initiatives in the areas of clinical trials, post-marketing safety, benefit-risk management, business development, integration, process design and regulatory interactions. Dr. Simon received his medical degree from Albert Szent-Gyorgyi Medical University in Hungary.

Mark Stanton

Mr. Mark Stanton is Vice President - Market Access and Corporate Accounts of the Company. He brings to AMAG more than 30 years of experience, most recently serving at AstraZeneca as the head of market access optimization since 2015 and the head of the U.S. diabetes market access function since 2013. From 2007 to 2013, Mr. Stanton served as the vice president for market access and reimbursement for Medimmune, Inc., an AstraZeneca Biologics Division. Prior to that, Mr. Stanton served in a variety of corporate accounts and sales roles at a number of pharmaceutical companies. Mr. Stanton holds a Bachelor of Science degree in business administration from Castleton State College, Vermont.

Nicholas Grund

Mr. Nicholas (Nik) Grund is Chief Commercial Officer of the Company. Prior to joining us, Mr. Grund served from 2002 to December 2015, in various positions of increasing responsibility at Genzyme Corporation, a Sanofi company ("Genzyme"), most recently as Head of Specialty Care. Prior to Genzyme, Mr. Grund progressed through a number of senior finance roles in the Critical Care Business Unit of Bayer Diagnostics from 1995 to 2002. Mr. Grund holds a B.S. in business administration from the University of Massachusetts and an M.B.A. from Northeastern University.

Barbara Deptula

Ms. Barbara H. Deptula is Independent Director of the Company. She served as the Executive Vice President of Business Development and Chief Corporate Development Officer of Shire Plc. ("Shire"), a public biopharmaceutical company, from 2004 to June 2012. Prior to joining Shire, Ms. Deptula served as President of the biotechnology division of SICOR, Inc. from 2003 to 2004. Prior to SICOR, Inc., Ms. Deptula served as Senior Vice President for Coley Pharmaceutical Group, Inc. from 2000 to 2003. Prior to 2000, she also held senior management positions in public and private pharmaceutical companies where Ms. Deptula focused on marketing, product development, licensing and business development, including US Bioscience, Inc., Schering Plough International, Lederle Laboratories, a division of American Cyanamid Co., U.S.A., and Genetics Institute. Ms. Deptula holds a B.S. in Pharmacy from the University of Connecticut's School of Pharmacy and an M.B.A. with a concentration in finance from the University of Chicago Booth School of Business.

John Fallon

Dr. John A. Fallon, M.D. is Independent Director of the company. He most recently served as senior vice president and chief physician executive at Blue Cross & Blue Shield of Massachusetts (BCBS) from 2004 to 2015. Prior to his role at BCBSMA, Dr. Fallon served as chief executive officer for clinical affairs at the State University of New York Downstate Medical Center, including University Hospital of Brooklyn and the clinical faculty practice plan. His professional experience also includes the Partners Healthcare System, where he was chairman of the physician network. Dr. Fallon was the founder and CEO of North Shore Health System, a large physician-hospital organization in Massachusetts. He serves as lead director for the board of directors of Insulet Corporation, and serves on the board of directors for Exact Sciences. He also serves on several not-for-profit boards, including NEHI (Network for Excellence in Health Innovation) (Chair), National Committee for Quality Assurance (NCQA) Medical Standards (Chair), New England Comparative Effectiveness Public Advisory Council (CEPAC) and Temple University School of Medicine Board of Advisors. Dr. Fallon practiced internal medicine for more than 20 years, fulfilled his residency at Boston City Hospital, is Board Certified in Internal Medicine and is a fellow of the American College of Physicians. He received a bachelor’s degree from the College of the Holy Cross, a master’s degree in business administration from the University of South Florida and a medical degree from Tufts University School of Medicine.

Robert Perez

Mr. Robert J. Perez is Independent Director of the Company. He is the founder and has been the Managing Partner at Vineyard Sound Advisors, LLC, a biopharmaceutical consulting firm, since March 2015. Mr. Perez is also the founder and has been the Chairman of the Board of Life Science Cares, a non-profit organization, since January 2016. He served as Chief Executive Officer of Cubist Pharmaceuticals, Inc. ("Cubist"), a public pharmaceutical company, from January 1, 2015 until Cubist was acquired by Merck & Co., Inc. later that month. Mr. Perez joined Cubist in 2003 as Senior Vice President, Sales and Marketing, and led the launch of Cubicin® (daptomycin for injection). He served as Executive Vice President and Chief Operating Officer from 2007 to July 2012 and President and Chief Operating Officer from July 2012 to December 2014. Prior to joining Cubist, he served as Vice President of Biogen, Inc.'s CNS business unit from 2001 to 2003, where he was responsible for commercial leadership of an $800 million neurology business unit, and from 1995 to 2001 he held positions of increasing responsibility within Biogen's CNS commercial organization. From 1987 to 1995 Mr. Perez held various sales and marketing positions at Zeneca Pharmaceuticals. Mr. Perez currently serves as a member of the Board of Trustees at the Dana-Farber Cancer Institute, Inc. and has been a member of the Board of Directors and the Compensation and Audit Committees of Cidara Therapeutics, Inc., a public biotechnology company, since March 2015 and a member of the Board of Directors and Compensation Committee of FlexPharma, a public biotechnology company, since September 2015. Mr. Perez has also been a member of the Board of Directors of Zafgen, Inc. a public biopharmaceutical company, since September 2015, where he has been a member of the Nominating and Governance Committee since March 2016. In addition, Mr. Perez has served as a member of the Board of Directors of Vir Biotechnology, Inc., a biotechnology company, since February 2017.

Cooper Russell

Dr. Cooper Lesley Russell is Independent Director of the Company. She has served as Chief Medical Officer of Innocoll Holdings plc, a public pharmaceutical company. She previously served as Chief Operating Officer of TetraLogic Pharmaceuticals, Inc., a public biopharmaceuticals company ("TetraLogic"), from August 2013 to April 2016. Prior to TetraLogic, she was Senior Vice President and Global Head of Research and Development for Global Branded Products at Teva Pharmaceuticals, Inc. ("Teva"), a public pharmaceutical company, from 2011 to June 2012. Dr. Russell was appointed to such role upon Teva's acquisition of Cephalon Inc. ("Cephalon"), a public pharmaceutical company, where she served as Executive Vice President and Chief Medical Officer from 2006 to 2011. She joined Cephalon in 2000 as Vice President, Worldwide Clinical Research. Prior to Cephalon, Dr. Russell served as Vice President, Clinical Research at US Bioscience Inc., a public pharmaceutical company, and held positions of increasing responsibility within US Bioscience Inc. from 1996 to 1999. From 1995 to 1996, she was a clinical research physician at Eli Lilly U.K. and a Medical Director at Amgen U.K. from 1992 to 1995. Dr. Russell has served on the Board of Directors of Enanta Pharmaceuticals, Inc., a public biotechnology company, since November 2016, where she is also a member of its Audit Committee and Nominating and Governance Committee. Dr. Russell also serves on the Board of Directors of Endocyte, Inc., a public biopharmaceutical company, where she has been a director since January 2013 and Melmark, Inc., a non-profit organization. Dr. Russell was trained in Hematology/Oncology at Royal Infirmary of Edinburgh and at Royal Hospital for Sick Children, Edinburgh. She received an MB.Ch.B. from the University of Edinburgh, Scotland and is a member of the Royal College of Physicians, United Kingdom. Dr. Russell is registered with the General Medical Council, United Kingdom.

Davey Scoon

Mr. Davey S. Scoon, CPA is Independent Director of the Company. He served as Chief Administrative and Financial Officer of Tom's of Maine, a company that manufactures natural care products from 2003 to 2005. From 2001 to 2003, Mr. Scoon served as Chief Financial and Administrative Officer for Sun Life Financial U.S., and from 1999 to 2001, Mr. Scoon served as Vice President and Chief Financial Officer for Sun Life Financial U.S. From 1985 to 1999, Mr. Scoon was employed by Liberty Funds Group of Boston (formerly Colonial Management) in various capacities, including Chief Financial Officer and Chief Operating Officer. Since May 2012, Mr. Scoon has been a member of the Board of Directors and the Chairman of the Audit Committee of Albireo Pharma, Inc. (formerly known as Biodel Inc.), a public biopharmaceutical company. Mr. Scoon currently serves as Chairman of the Board of Trustees of Allianz Funds, a registered investment company, where he has been a director since January 2006. Mr. Scoon was also a member of the Board of Directors and the Audit Committee of Orthofix International, N.V., a medical device company, from 2011 to June 2015. Mr. Scoon has been an Adjunct Professor at the University of Wisconsin-Madison since 2011. Mr. Scoon holds a B.B.A. from the University of Wisconsin and an M.B.A. from Harvard Business School.

James Sulat

Mr. James R. Sulat serves as Independent Director of the Company. He served as the chief executive officer and chief financial officer of Maxygen, Inc. from 2009 to 2013, and as a member of its board of directors from 2003 to 2013. From 2005 to 2009, Mr. Sulat served as president and chief executive officer and then as chief financial officer of Memory Pharmaceuticals Corp. from 2005 to 2008, as well as a member of its board of directors from 2005 to 2009. Prior to these roles, Mr. Sulat was the chief financial officer in several different large and mid-sized public companies. Mr. Sulat serves as chairman of the board of directors for Momenta Pharmaceuticals, Inc., and on the board of directors of Arch Therapeutics, Inc., Diadexus, Inc., and Valneva SE. Mr. Sulat received a BS in Administrative Sciences from Yale University, and a MBA and a M.S in Health Services Administration from Stanford University.

Linda Lennox

Ms. Linda Lennox is Vice President of Investor Relations, & Corporate Communications of AMAG Pharmaceuticals, Inc. Ms. Lennox has 25 years of leadership experience with companies in the healthcare and energy sectors. Prior to joining AMAG, Ms. Lennox served as senior director, investor relations & corporate communications at Lantheus Medical Imaging, Inc., a privately held global diagnostic imaging company. Prior to that, Ms. Lennox served as vice president, investor & media relations at Critical Therapeutics, a publicly traded biotechnology/specialty pharmaceutical company. Prior to joining Critical Therapeutics, Ms. Lennox spent 15 years in positions of increasing responsibility at two separate publicly traded energy companies. Ms. Lennox started her career at Putnam Investments and Smith Barney, where she obtained her series 6, 7 and 63 licenses. She received a bachelor's degree in economics from the University of Vermont.